EPZM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States...

Stats
Today's Volume	0.00
Average Volume	4.18M
Market Cap	0.00
EPS	$-0.210 ( 2022-08-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.704
ATR14	$0.0490 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-12	Giordano Michael F	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	13 060	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	3 380 951	Common Stock, par value $0.0001
2022-08-12	Conroy Kevin T	Sell	53 324	Common Stock, par value $0.0001

INSIDER POWER
-88.96
Last 98 transactions
Buy: 31 679 726 \| Sell: 42 571 145

Volume Correlation

Long: 0.22 (neutral)

Short: -0.56 (weak negative)

Signal:(61.298) Neutral

Epizyme Inc Correlation

10 Most Positive Correlations
APOP	0.959
RMRM	0.951
MEIP	0.933
PCVX	0.93
NNOX	0.927
RAPT	0.927
NERV	0.926
TYHT	0.925
CVGI	0.922
PRTA	0.921

10 Most Negative Correlations
TWKS	-0.955
SMSI	-0.925
INFI	-0.922
UPLD	-0.921
OM	-0.92
DTEA	-0.919
VNET	-0.916
EYE	-0.913
SBBP	-0.913
REPL	-0.912

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Epizyme Inc Correlation - Currency/Commodity

0.60
( weak )

0.00
( neutral )

0.53
( weak )

-0.74
( moderate negative )

-0.25
( neutral )

Epizyme Inc Financials

Annual	2021
Revenue:	$37.43M
Gross Profit:	$26.93M (71.95 %)
EPS:	$-2.45

Q2	2022
Revenue:	$27.53M
Gross Profit:	$22.33M (81.11 %)
EPS:	$-0.250

Q1	2022
Revenue:	$8.70M
Gross Profit:	$6.10M (70.10 %)
EPS:	$-0.380

Q4	2021
Revenue:	$11.58M
Gross Profit:	$8.43M (72.78 %)
EPS:	$-0.490

Financial Reports:

No articles found.

Epizyme Inc

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..